Tirbanibulin Research for Actinic Keratosis to be Presented at EADV

Almirall will present eight abstracts detailing the latest research on tirbanibulin for actinic keratosis at the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), the company announced.

The EADV takes place September 25-28 in Amsterdam, Netherlands.

Almirall’s abstracts for tirbanibulin, which it offers under the brand name Klisyri®, are:

• Lack of correlation between number of baseline actinic keratoses and local tolerability signs severity in patients treated with tirbanibulin over a 100 cm2 area: results from a Phase 3 study
• Real-world evidence of tirbanibulin for actinic keratosis in Germany. Insights into patient-reported outcomes, safety and effectiveness
• Efficacy and safety of tirbanibulin 1% ointment for the treatment of actinic keratosis in conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)
• Patient and physician-reported outcomes with tirbanibulin 1% ointment for actinic keratosis in conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)
• Enhancement of sun-damaged skin qualities with tirbanibulin (SunDamage Study)
• Actinic cheilitis: Diagnosis and monitoring after treatment with Tirbanibulin using optical coherence tomography
• Diagnosis and treatment of patients with actinic keratosis in France: REAKT study Actinic keratosis in France: an avoidable risk of skin cancer, unexpectedly also for people aged under 65 years (REAKT study)
• Actinic keratosis in France: disease perceptions, expectations, and behaviors of patients (REAKT study).